Stacy A. Rudnicki

Neurology
4301 W Markham St
Little Rock, AR 72205

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALS.

The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALS.

Journal: Muscle & nerve
Published: October 29, 2025

Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial.

Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: June 27, 2025

Hospitalizations as an outcome measure in COURAGE-ALS.

Hospitalizations as an outcome measure in COURAGE-ALS.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: June 12, 2025

Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALS.

Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALS.

Journal: Journal of neuromuscular diseases
Published: May 05, 2025

Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial.

Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial.

Journal: JAMA neurology
Published: March 24, 2025

Plasma neurofilament analysis in VITALITY-ALS.

Plasma neurofilament analysis in VITALITY-ALS.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: November 08, 2024

Time from amyotrophic lateral sclerosis symptom onset to key disease milestones: analysis of data from a multinational cross-sectional survey.

Time from amyotrophic lateral sclerosis symptom onset to key disease milestones: analysis of data from a multinational cross-sectional survey.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: December 29, 2023

Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial.

Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: August 29, 2023

COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.

COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: May 31, 2023

Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS.

Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS.

Journal: Journal of medical economics
Published: March 17, 2023

MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial.

MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: December 12, 2022

Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.

Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: November 03, 2021
Showing 1-12 of 30

Last Updated: 09/26/2026